OBJECTIVES: To conduct a cost – utility analysis of the AbbVie’s regimen versus other established maintenance treatment options in the Greek health care setting, for patients within genotype 1b chronic hepatitis C virus (HCV). METHODS: A Markov model was adapted locally to reflect the natural progression of patients with genotype 1b through different health states. Efficacy and safety data considered in the model were extracted from the relevant clinical trials and other published studies. Utilities values were extracted from the literature. Direct medical costs were incorporated in the model reflecting the year 2015. The model evaluated the comparators over a lifetime horizon in the course of a 1-year cycle. The outcomes are measured in terms of Quality Adjusted Life Years gained. While outcomes can vary, the outcomes in this analysis were measured in terms of life-years gained. The analysis was performed from a payer’s perspective. Costs and outcomes that occurred beyond one year were discounted at a 3.5% annual rate which is the standard practice in Greece as well as other jurisdictions. RESULTS: The base case results indicate that the AbbVie Regimen is a dominant option (in the most cases) and cost-effective option for naïve patients with genotype 1b HCV. The sensitivity analysis shows that the overall cost-effectiveness results are sensitive to the model time horizon and changes in the SVR rate for patients on the comparator treatment. AbbVie’s regimen appears cost-effective based on traditional standards in the vast majority of sensitivity analyses. In the CEAF, it is the optimal choice (on the optimality frontier) when payers are willing to pay over about 15,000€/QALY in the majority of analyses. CONCLUSIONS: Using conservative assumptions, the present economic evaluation suggests that AbbVie’s regimen provides greater health outcomes and is less costly compared to majority of comparators.